Patents Assigned to Centro de Immunologia Molecular
-
Patent number: 10000573Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.Type: GrantFiled: May 31, 2017Date of Patent: June 19, 2018Assignees: CENTRO DE IMMUNOLOGIA MOLECULAR, BIOCON LIMITEDInventors: Ramakrishnan Melarkode, Pradip Nair, Sundaraj David Rajkumar, Kedarnath Nanjund Sastry, Monalisa Chatterji, Laxmi Adhikary, Hema Balasubramanian, Jose Enrique Montero Casimiro, Josefa Lombardero Valladares, Rolando Perez Rodriguez
-
Patent number: 9790279Abstract: The present invention relates to pharmaceutical compositions for the treatment of malignant tumors. Particularly those tumors that express EGFR and GM3 N-glycolyl ganglioside targets to enhance the therapeutic effect produced by separated therapies against these targets. The pharmaceutical compositions of the invention include antibodies and/or vaccines against each of the targets. Additionally the present invention relates to methods for applying the compositions of the invention.Type: GrantFiled: December 4, 2012Date of Patent: October 17, 2017Assignee: CENTRO DE IMMUNOLOGIA MOLECULARInventors: Adys González Palomo, Adriana Carr Perez, Kalet León Monzón, Rancés Blanco Santana, María del Carmen Barroso Alvarez, Amparo Emilia Macías Abraham, José Enrique Montero Casimiro
-
Patent number: 9527920Abstract: The present invention relates to new monoclonal antibodies and fragments of these antibodies, which have dual specificity and high affinity for N-acetyl GM3 and N-glycolyl GM3 and do not recognize other gangliosides. In another aspect, the present invention relates to the use of these antibodies and their fragments in the therapy of tumors characterized by a significant expression of any of the two antigens recognized by these antibodies, or a mixed expression of both antigens. Likewise, the invention relates to the use of these antibodies in the diagnosis of tumors expressing at least one of the two variants of the GM3 ganglioside.Type: GrantFiled: February 21, 2013Date of Patent: December 27, 2016Assignee: CENTRO DE IMMUNOLOGIA MOLECULARInventors: Ernesto Moreno Frias, Gertrudis Rojas Dorantes, Ana Victoria Casadesus Pazos
-
Patent number: 9206243Abstract: The present invention relates to polypeptides which share primary sequence with human IL-2, except for several amino acids that have been mutated. The mutations introduced substantially reduce the ability of these polypeptides to stimulate in vitro and in vivo regulatory T cells (T CD4+CD25+FoxP3+) and make them more effective in the therapy of murine transplantable tumors. Also includes therapeutic uses of these mutated variants, used alone or in combination with vaccines for the therapy of diseases such as cancer or infections where the activity of regulatory T cells (Tregs) is relevant. In another aspect the present invention relates to pharmaceutical compositions comprising as active principle the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptides and pharmaceutical compositions disclosed due to their modulating effect of the immune system on diseases like cancer and chronic infectious diseases.Type: GrantFiled: November 10, 2011Date of Patent: December 8, 2015Assignee: CENTRO DE IMMUNOLOGIA MOLECULARInventors: Kalet León Monzón, Tania Carmenate Portilla, Saumel Pérez Rodriguez, Neris Michel Enamorado Escalona, Agustin Bienvenido Lage Dávila
-
Patent number: 8841251Abstract: A vaccine composition for therapeutic use thereof on cancer patients includes a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and a combining protein P64k for performing a conjugation reaction which produces said chemical conjugate in a controlled and reproducible manner. The preferred conjugate surprisingly increases the immunogenic activity causing significant increases in the anti-EGF antibody titers in humans, and provides a vaccine preparation with more than one type of effective dose presentation which enables the immunization dose per patient to be increased, but without involving an increase in immunization frequency and/or the number of immunization sites.Type: GrantFiled: January 10, 2012Date of Patent: September 23, 2014Assignee: Centro de Immunologia Molecular (CIM)Inventors: Gryssell Rodriguez Martinez, Lisel Vina Rodriguez, Loany Calvo Gonzalez, Ariadna Cuevas Fiallo, Ernesto Chico Veliz, Agustin Bienvenido Lage Davila, Tania Crombet Ramos, Arama Albisa Novo, Gisela Maria Gonzalez Marinello
-
Patent number: 8697093Abstract: The present invention relates to the field of biotechnology applied to human health. The invention describes a vaccine vehicle which toxins from eukaryotic organisms are encapsulated in liposomes with multiple lipid layers, obtained by means of the process of dehydration/rehydration, the lipid composition of which is dipalmitoylphosphatidylcholine:cholesterol in a molar ration of 1:1, which are designed for subcutaneous or intramuscular administration. These compositions do not require the use of other adjuvants. The compositions described allow modulation of the specific CTL immune response to one or more antigens co-encapsulated in the liposomes that containing the toxin. The vaccine vehicle of the present invention presents advantages as compared with others described in the prior art owning to the robust and functional nature of the immune response induced and also the immunomodulating properties thereof.Type: GrantFiled: July 5, 2011Date of Patent: April 15, 2014Assignee: Centro De Immunologia MolecularInventors: Maria Eliana Lanio Ruiz, Luis Enrique Fernández Molina, Rady Judith Laboroe Quintana, Yoelys Cruz Leal, Maria del Carmen Luzardo Lorenzo, Circe Mesa Pardillo, Carlos Manuel Alvarez Valcárcel, Isabel Fabiola Pazos Santos, Mayra Tejuca Martínez, Aisel Valle Garay, Maria Eugenia Alonso Biosca, Liem Canet Santos
-
Patent number: 8524233Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.Type: GrantFiled: September 4, 2008Date of Patent: September 3, 2013Assignee: Biocon Limited & Centro de Immunologia MolecularInventors: Ramakrishnan Melarkode, Pradip Nair, Sundaraj David Rajkumar, Kedarnath Nanjund Sastry, Monalisa Chatterji, Laxmi Adhikary, Hema Balasubramanian, Jose Enrique Montero Casimiro, Josefa Lombardero Valladares, Rolando Perez Rodriguez
-
Patent number: 7776342Abstract: This invention discloses means for obtaining immunogenic peptides, polypeptides, proteins, and their corresponding nucleic acid sequences, target cells with vaccine interest, or lysates thereof, without making structural changes in said antigens, through their association with Very Small Size Proteoliposomes. The object of the invention is to provide immunogenic compositions containing peptides, polypeptides, proteins, their corresponding DNA sequences, cells or their lysates and Very Small Size Proteoliposomes (VSSP), which are formed by binding the Outer Membrane Protein Complex (OMPC) of Neisseria meningitidis with gangliosides, by means of hydrophobic links. Additionally, it is stated that these compositions can be formulated alone or in the form of emulsions with the Incomplete Freund's Adjuvant (IFA), and may also be lyophilized.Type: GrantFiled: December 6, 2001Date of Patent: August 17, 2010Assignee: Centro de Immunologia MolecularInventors: Luis Enrique Fernandez Molina, Belinda Sanchez Ramirez, Eduardo Raul Suarez Pestana, Anabel de la Barrera Aira, Circe Mesa Pardillo, Joel de Leon Delgado, Yildian Diaz Rodriguez, Rolando Perez Rodriguez
-
Patent number: 6433148Abstract: The present invention describes the selection and use of antidiotypic monoclonal antibodies. (AB2) IgG type with the main characteristic of being highly connected to the idiotipic network and recognition of B and T human lymphocytes, which are major participants in the immune response. According to the previous statement the objective of this invention is to provide antidiotypic monoclonal antibodies IgG type connected to the immune network, able to interact with T and B lymphocytes and able to exert an immunoregulatory effect, irmunostimulation or immunosupression that can be used for immunotherapy of autoimune diseases, infectious diseases and cancer.Type: GrantFiled: November 17, 1997Date of Patent: August 13, 2002Assignee: Centro de Immunologia Molecular (CIM)Inventors: Amparo Emilia Macias Abrahan, Rolando Perez Rodriguez, Teresita Rodriguez Obaya, Mercedes Ramos Zamora, Gumersinda Bombino Lopez, Orlando Pena Marichal
-
Patent number: 5894018Abstract: The invention provides novel uses of EGF and vaccine compositions comprising EGF. In particular, autologous EGF, or a fragment or a derivative thereof, is used as an active immunization against the proliferation of EGF-dependent tumors, or other EGF-dependent diseases. Autologous EGF is preferably coupled to a carrier protein, such as tetanus toxoid or Cholera toxin B chain. The vaccine compositions according to the invention will usually comprise an adjuvant such as aluminum hydroxide.Type: GrantFiled: February 21, 1996Date of Patent: April 13, 1999Assignee: Centro De Immunologia MolecularInventors: Augustin Bienvenido Lage Davila, Gisela Gonzalez Marinello, Belinda Sanchez Ramirez, Eduardo Suarez Peztana, Irene Beausoleil Delgado, Gilda Nurez Gandolf
-
Patent number: 5712120Abstract: Modified chimaeric antibodies, and antibody heavy and light chains, which comprise variable domains derived from a first mammalian species, usually mouse, and constant domains from a second mammalian species, usually human. Modification concerns the variable domains, in particular the framework regions of the variable domains. The modifications are made only in T-cell antigenic structures present in framework regions, and do not cover canonical structures or Vernier zone. The modifications adapt the amino acid sequences concerned to those occurring in corresponding antibodies derived from said second mammalian species. Thus, the modified chimaeric antibodies retain the original antigen recognition and binding properties but become less immunogenic to said second mammalian species, which improves their therapeutical utility with said second mammalian species. Recombinant DNA technology may be used to construct and produce the modified chimaeric antibodies.Type: GrantFiled: June 30, 1995Date of Patent: January 27, 1998Assignee: Centro De Immunologia MolecularInventors: Rolando Perez Rodriguez, Christina Maria Mateo de Acosta del Rio, Josefa Lombardero Valladares